Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Mankin

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Molecular Oncology|February 2, 2017
miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivoZhenfeng Duan, Yan Gao, Jacson Shen, et al.
Oncotarget|April 19, 2017
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cellsYunfei Liao, Lulu Chen, Yong Feng, et al.
Molecular Cancer Therapeutics|September 3, 2009
A novel target for treatment of chordoma: signal transducers and activators of transcription 3Cao Yang, Joseph H Schwab, Andrew J Schoenfeld, et al.
Journal of Medicinal Chemistry|March 10, 2012
Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancerZhenfeng Duan, Xin Li, Haoxi Huang, et al.
Plos One|October 3, 2013
Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordomaLinlin Zhang, Shang Guo, Joseph H Schwab, et al.
Gynecologic Oncology|February 14, 2015
NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivoXiaoqian Yang, Yong Feng, Yan Gao, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2006
Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumorLily Park, Thomas F Delaney, Norbert J Liebsch, et al.
Scientific Reports|August 11, 2018
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
Scientific Reports|March 7, 2017
Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
BMC Cancer|September 20, 2014
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cellsZhenfeng Duan, Jianming Zhang, Shunan Ye, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Molecular Oncology|February 2, 2017
miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivoZhenfeng Duan, Yan Gao, Jacson Shen, et al.
Oncotarget|April 19, 2017
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cellsYunfei Liao, Lulu Chen, Yong Feng, et al.
Molecular Cancer Therapeutics|September 3, 2009
A novel target for treatment of chordoma: signal transducers and activators of transcription 3Cao Yang, Joseph H Schwab, Andrew J Schoenfeld, et al.
Journal of Medicinal Chemistry|March 10, 2012
Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancerZhenfeng Duan, Xin Li, Haoxi Huang, et al.
Plos One|October 3, 2013
Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordomaLinlin Zhang, Shang Guo, Joseph H Schwab, et al.
Gynecologic Oncology|February 14, 2015
NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivoXiaoqian Yang, Yong Feng, Yan Gao, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2006
Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumorLily Park, Thomas F Delaney, Norbert J Liebsch, et al.
Scientific Reports|August 11, 2018
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
Scientific Reports|March 7, 2017
Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
BMC Cancer|September 20, 2014
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cellsZhenfeng Duan, Jianming Zhang, Shunan Ye, et al.
Pageof 6